BUSINESS
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
CNBC BusinessFriday, October 2, 2026 at 5:55 PM
RedScroll Brief
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
RedScroll Signal
- Impact
- High
- Category
- Business
- Market relevance
- High
- Why it matters
- Corporate and market moves reprice risk and reveal where power and cash are concentrating. Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes. Investors will watch earnings, rates, and competitive positioning connected to Why Lilly and Novo.
Desk copy
RedScroll Briefing
Extractive editorial brief — not a reprint of the original
What happened
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Why it matters
Corporate and market moves reprice risk and reveal where power and cash are concentrating.
Background
CNBC Business reported on this under business. RedScroll surfaces the signal with an extractive brief — not a reprint of the original article. Read the source for full reporting.
Timeline
CNBC Business published: Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Story is in today’s RedScroll edition. Follow the original source for updates.
Economic impact
Investors will watch earnings, rates, and competitive positioning connected to Why Lilly and Novo.
More on
Related stories
- Traders now see little chance of a Fed rate hike in October after weak jobs report
CNBC FinanceBUSINESS
- Burger King is betting on local franchisees to fuel its U.S. comeback
CNBC BusinessBUSINESS
- Mattel shares rise after reports of takeover interest from Authentic Brands Group
CNBC BusinessBUSINESS
- You’re not sending an email. You’re training a model
The Economist BusinessBUSINESS
- The Swiss watch industry is shrinking—but getting swankier
The Economist BusinessBUSINESS
- A rocket shortage gives SpaceX’s competitors an opportunity
The Economist BusinessBUSINESS
Source
CNBC Business
Original reporting by CNBC Business. RedScroll provides an extractive briefing only.